Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia
Yıl: 2021 Cilt: 49 Sayı: 4 Sayfa Aralığı: 286 - 292 Metin Dili: İngilizce DOI: 10.5543/tkda.2021.87750 İndeks Tarihi: 29-01-2022
Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia
Öz: Objective: To compare the prevalence of hypertension and pre-existing use of renin-angiotensin-aldosterone system blockers in patients with coronavirus disease (COVID-19) and non-COVID-19 viral pneumonias. Methods: Real-time polymerase chain reaction confirmed COVID-19 and non-COVID-19 pneumonia patients were retrospectively analyzed. The presence of hypertension, coronary artery disease (CAD), and pre-existing use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) were compared between the groups. Results: A total of 103 COVID-19 and 91 non-COVID-19 hospitalized viral pneumonia patients were enrolled. Hypertension and CAD were more common in patients with nonCOVID-19 viral pneumonia than in patients with COVID-19 (39.6% vs 22.3%, respectively, p=0.012 and 24.2% vs 4.9%, respectively, p<0.001). In our study, 2.9% and 6.8% of patients with COVID-19 were on ACEIs and ARBs, respectively, whereas 13.2% and 19.8% of patients with non-COVID-19 viral pneumonia were on ACEIs and ARBs, respectively (p=0.009 and p=0.013). Neutrophil-to-lymphocyte ratio (p<0.001) was prominent in patients with non-COVID-19 viral pneumonia compared with patients with COVID-19. Conclusion: Our study results indicate that hypertension and CAD are more common among patients with non-COVID-19 viral pneumonia than patients with COVID-19. The prevalence of ACEIs and ARBs use was not higher in patients with COVID-19. Our results support that the use of ACEIs and ARBs do not play a specific role in patients with COVID-19.
Anahtar Kelime: Hipertansiyon prevalansı ve renin-anjiyotensin-aldosteron sistemi blokerleri kullanımının COVID-19 ve COVID-19 dışı viral pnömoni hastalarında karşılaştırılması
Öz: Amaç: COVID-19 ve COVID-19 dışı viral pnömoni hastalarında hipertansiyon prevalansı ve önceden renin-anjiyotensin-aldosteron blokeri kullanımının karşılaştırılmasıdır. Yöntemler: Gerçek-zamanlı polimeraz zincir reaksiyonu (RT-PCR) ile doğrulanmış COVID-19 pnömoni hastaları ile COVID-19 dışı viral pnömoni hastaları retrospektif olarak incelendi. Gruplar arasında hipertansiyon ve koroner arter hastalığı (KAH) varlığı ile önceden anjiyotensin dönüştürücü enzim inhibitörü (ADEİ) ve anjiyotensin reseptör blokeri (ARB) kullanımları karşılaştırıldı. Bulgular: Çalışmaya hastanede yatarak tedavi gören 103 COVID-19 ve 91 COVID-19 dışı viral pnömoni hastası dahil edildi. Hipertansiyon ve KAH, COVID-19 dışı viral pnömoni hastalarında daha sıktı (%39.6’ya karşılık %22.3, sırasıyla, p=0.012 ve %24.2’ye karşılık %4.9, sırasıyla, p<0.001). COVID-19 hastalarının %2.9’u ADEİ ve %6.8’i ARB kullanmaktaydı. Buna karşılık COVID-19 dışı viral pnömoni hastalarının sırasıyla %13.2’si ve %19.8’i ADEİ ve ARB kullanmaktaydı (p=0.009 ve p=0.013). Nötrofil/lenfosit oranı (NLR) COVID-19 dışı viral pnömoni hastalarında belirgin olarak daha yüksekti (p<0.001). Sonuç: Çalışmamız hipertansiyon ve KAH sıklığının COVID-19 dışı viral pnömonili hastalarında COVID-19 hastalarına kıyasla daha fazla olduğuna işaret etmektedir. COVID-19 hastalarında ADEİ ve ARB kullanım prevalansı COVID-19 dışı pnömonili hastalardan daha yüksek değildi. Çalışmamızın sonuçları ADEİ ve ARB kullanımının COVID-19 hastalarında özel bir rol oynamadığını desteklemektedir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. [Crossref]
- 2. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet 2020;395:1225- 8. [Crossref]
- 3. Bernard Stoecklin S, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill 2020;25:pii=2000094. [Crossref]
- 4. World Health Organization. Available at: https://www.who. int/dg/speeches/detail/who-director-generals-remarks-atthe-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed February 12, 2020).
- 5. WHO Director-General’s opening remarks at the media briefing on COVID-19: 11 March 2020. March 11, 2020. Available at: https://www.who.int/dg/speeches/detail/whodirector-general-s-opening-remarks-at-themedia-briefingon-covid-19---11-march-2020 (Accessed March 30, 2020).
- 6. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934-43. [Crossref]
- 7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9. [Crossref]
- 8. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China Medical Treatment Expert Group for Covid-19. clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
- 9. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-80. [Crossref]
- 10. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8:e21. [Crossref]
- 11. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17:259-60. [Crossref]
- 12. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med 2020;382:2431-40. [Crossref]
- 13. Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J 2020;41:2058-66. [Crossref]
- 14. Clinical management of COVID-19. Interim guidance. Available at: https://www.who.int/publications/i/item/clinical-management-of-covid-19. (Accessed May 27, 2020).
- 15. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community acquired pneumonia in adults. Clin Infect Dis 2007;44:27-72.
- 16. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet 2011;377:1264-75. [Crossref]
- 17. Dandachi D, Rodriguez-Barradas MC. Viral pneumonia: etiologies and treatment. J Investig Med 2018;66:957-965. [Crossref]
- 18. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020;63:457-60. [Crossref]
- 19. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281-92.e6. [Crossref]
- 20. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med 2020;76:14-20. [Crossref]
- 21. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, 2020. China CDC Weekly 2020;2:113-22. [Crossref]
- 22. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020;323:1239-42. [Crossref]
| APA | Görmez S, Kirisoglu C, EKİCİBAŞI M, Değirmencioğlu A, Paudel A, akan g, Atalar F, Sarıgüzel N, PAMUKÇU B (2021). Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia. , 286 - 292. 10.5543/tkda.2021.87750 |
| Chicago | Görmez Selçuk,Kirisoglu Ceyda Erel,EKİCİBAŞI MEHMET ERKAN,Değirmencioğlu Aleks,Paudel Ashok,akan gokce,Atalar Fatmahan,Sarıgüzel Nevin,PAMUKÇU BURAK Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia. (2021): 286 - 292. 10.5543/tkda.2021.87750 |
| MLA | Görmez Selçuk,Kirisoglu Ceyda Erel,EKİCİBAŞI MEHMET ERKAN,Değirmencioğlu Aleks,Paudel Ashok,akan gokce,Atalar Fatmahan,Sarıgüzel Nevin,PAMUKÇU BURAK Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia. , 2021, ss.286 - 292. 10.5543/tkda.2021.87750 |
| AMA | Görmez S,Kirisoglu C,EKİCİBAŞI M,Değirmencioğlu A,Paudel A,akan g,Atalar F,Sarıgüzel N,PAMUKÇU B Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia. . 2021; 286 - 292. 10.5543/tkda.2021.87750 |
| Vancouver | Görmez S,Kirisoglu C,EKİCİBAŞI M,Değirmencioğlu A,Paudel A,akan g,Atalar F,Sarıgüzel N,PAMUKÇU B Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia. . 2021; 286 - 292. 10.5543/tkda.2021.87750 |
| IEEE | Görmez S,Kirisoglu C,EKİCİBAŞI M,Değirmencioğlu A,Paudel A,akan g,Atalar F,Sarıgüzel N,PAMUKÇU B "Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia." , ss.286 - 292, 2021. 10.5543/tkda.2021.87750 |
| ISNAD | Görmez, Selçuk vd. "Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia". (2021), 286-292. https://doi.org/10.5543/tkda.2021.87750 |
| APA | Görmez S, Kirisoglu C, EKİCİBAŞI M, Değirmencioğlu A, Paudel A, akan g, Atalar F, Sarıgüzel N, PAMUKÇU B (2021). Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia. Türk Kardiyoloji Derneği Arşivi, 49(4), 286 - 292. 10.5543/tkda.2021.87750 |
| Chicago | Görmez Selçuk,Kirisoglu Ceyda Erel,EKİCİBAŞI MEHMET ERKAN,Değirmencioğlu Aleks,Paudel Ashok,akan gokce,Atalar Fatmahan,Sarıgüzel Nevin,PAMUKÇU BURAK Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia. Türk Kardiyoloji Derneği Arşivi 49, no.4 (2021): 286 - 292. 10.5543/tkda.2021.87750 |
| MLA | Görmez Selçuk,Kirisoglu Ceyda Erel,EKİCİBAŞI MEHMET ERKAN,Değirmencioğlu Aleks,Paudel Ashok,akan gokce,Atalar Fatmahan,Sarıgüzel Nevin,PAMUKÇU BURAK Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia. Türk Kardiyoloji Derneği Arşivi, vol.49, no.4, 2021, ss.286 - 292. 10.5543/tkda.2021.87750 |
| AMA | Görmez S,Kirisoglu C,EKİCİBAŞI M,Değirmencioğlu A,Paudel A,akan g,Atalar F,Sarıgüzel N,PAMUKÇU B Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia. Türk Kardiyoloji Derneği Arşivi. 2021; 49(4): 286 - 292. 10.5543/tkda.2021.87750 |
| Vancouver | Görmez S,Kirisoglu C,EKİCİBAŞI M,Değirmencioğlu A,Paudel A,akan g,Atalar F,Sarıgüzel N,PAMUKÇU B Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia. Türk Kardiyoloji Derneği Arşivi. 2021; 49(4): 286 - 292. 10.5543/tkda.2021.87750 |
| IEEE | Görmez S,Kirisoglu C,EKİCİBAŞI M,Değirmencioğlu A,Paudel A,akan g,Atalar F,Sarıgüzel N,PAMUKÇU B "Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia." Türk Kardiyoloji Derneği Arşivi, 49, ss.286 - 292, 2021. 10.5543/tkda.2021.87750 |
| ISNAD | Görmez, Selçuk vd. "Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia". Türk Kardiyoloji Derneği Arşivi 49/4 (2021), 286-292. https://doi.org/10.5543/tkda.2021.87750 |
